Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

Antti Siltanen

Analyst

Antti Siltanen portrait

Coverage

Herantis PharmaNexstimFaron PharmaceuticalsNightingale HealthBioretecAiforia TechnologiesBiohitOrionModulight

Latest content

ShowingAll content types

Herantis received 8 MEUR in EU funding for Phase II trial

Analyst Comment 20.02.2026 klo 08.57 by Antti Siltanen
Herantis Pharma

Nexstim's NBS 6 received MDR certification for post-operative rehabilitation

Analyst Comment 20.02.2026 klo 08.48 by Antti Siltanen
Nexstim

Faron expands its bexmarilimab study to a new patient group

Analyst Comment 20.02.2026 klo 08.45 by Antti Siltanen
Faron Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account

Modulight Q4'25 preview: Finishing touches on a year of growth

Analyst Comment 18.02.2026 klo 09.15 by Antti Siltanen
Modulight

Nexstim navigates its way to the United Arab Emirates

Analyst Comment 17.02.2026 klo 08.23 by Antti Siltanen
Nexstim

Bioretec Q4'25: Groundwork for improved commercial execution

Research 16.02.2026 klo 10.35 by Antti Siltanen
Bioretec

Herantis strengthened its financial position via directed share issue

Analyst Comment 12.02.2026 klo 09.39 by Antti Siltanen
Herantis Pharma

Faron updated its research and financing plans

Analyst Comment 12.02.2026 klo 10.24 by Antti Siltanen
Faron Pharmaceuticals

Biohit H2'25: Strong earnings – more moderate growth outlook

Research 12.02.2026 klo 10.16 by Antti Siltanen
Biohit

Bioretec Q4'25 preview: Expectations for the rest of the year are at a moderate level

Analyst Comment 11.02.2026 klo 08.53 by Antti Siltanen
Bioretec
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.